(Q40393459)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7523702%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

review article

1 reference

title

The clinical usefulness of prostate specific antigen: update 1994 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7523702%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

The Clinical Usefulness of Prostate Specific Antigen: Update 1994 (English)

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

16 May 2024

author name string

A. W. Partin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7523702

16 May 2024

J. E. Oesterling

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7523702

16 May 2024

language of work or name

English

0 references

publication date

1 November 1994

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7523702%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

20 October 2019

https://api.elsevier.com/content/article/PII:S0022534717324229?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

https://api.elsevier.com/content/article/PII:S0022534717324229?httpAccept=text/plain

16 May 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

http://www.jurology.com/doi/pdf/10.1016/S0022-5347%2817%2932422-9

16 May 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

16 May 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7523702%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

volume

152

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7523702%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

issue

5 Pt 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7523702%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

page(s)

1358-1368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7523702%20AND%20SRC:MED&resulttype=core&format=json

Precipitating antigens of the normal human prostate.

20 October 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Purification of a human prostate specific antigen

16 May 2024

3

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay

16 May 2024

4

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers

16 May 2024

6

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

16 May 2024

7

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

16 May 2024

8

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate

16 May 2024

9

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

16 May 2024

13

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer

16 May 2024

14

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Questioning the value of screening for prostate cancer in asymptomatic men

16 May 2024

18

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Screening for prostate cancer: enthusiasm

16 May 2024

19

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

16 May 2024

Cancer statistics, 1993

20

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Adenocarcinoma of the prostate: results of routine urological screening

16 May 2024

21

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Early detection of prostate cancer by routine screening

16 May 2024

22

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Cancer of the prostate gland. Results of early diagnosis and therapy undertaken for cure of the disease

16 May 2024

23

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen--a screening test for prostatic cancer?

16 May 2024

25

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

16 May 2024

26

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Early detection program for prostate cancer: results and identification of high-risk patient population

16 May 2024

27

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Screening for prostatic carcinoma with prostate specific antigen: results of the second year.

16 May 2024

29

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Serum prostate specific antigen as pre-screening test for prostate cancer

16 May 2024

30

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate Cancer Detection in a Clinical Urological Practice by Ultrasonography, Digital Rectal Examination and Prostate Specific Antigen

16 May 2024

31

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Using PSA to screen for prostate cancer. The Washington University experience

16 May 2024

32

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters

16 May 2024

33

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer

16 May 2024

36

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen

16 May 2024

37

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

PSA density (PSAD). Role in patient evaluation and management

16 May 2024

38

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma.

16 May 2024

43

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease

16 May 2024

44

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

PSA velocity for the diagnosis of early prostate cancer. A new concept

16 May 2024

46

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges

16 May 2024

50

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases

16 May 2024

52

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate-specific antigen: critical issues for the practicing physician

16 May 2024

53

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.

16 May 2024

56

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Cancer Control following Anatomical Radical Prostatectomy: An Interim Report

16 May 2024

57

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate-specific antigen and external beam radiation therapy in prostate cancer

16 May 2024

58

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma

16 May 2024

59

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate tumour markers as an aid in the staging of prostatic cancer

16 May 2024

60

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The value of serum prostate specific antigen determinations before and after radical prostatectomy

16 May 2024

61

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade

16 May 2024

62

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

16 May 2024

63

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate-specific antigen: concepts for staging prostate cancer and monitoring response to therapy

16 May 2024

64

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Histologic Grade, DNA Ploidy, and Intraglandular Tumor Extent as Indicators of Tumor Progression of Clinical Stage B Prostatic Carcinoma

16 May 2024

65

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

PSA and staging of localized prostate cancer

16 May 2024

66

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND

16 May 2024

67

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients

16 May 2024

70

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The Value of Serum Enzymatic Acid Phosphatase in the Staging of Localized Prostate Cancer

16 May 2024

71

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer

16 May 2024

72

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy

16 May 2024

73

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Recurrent Prostate Cancer Despite Undetectable Prostate Specific Antigen

16 May 2024

74

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostatic Specific Antigen Related to Clinical Status 1 to 14 Years after Radical Retropubic Prostatectomy

16 May 2024

75

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

16 May 2024

76

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The Effect of Radiation Therapy after Radical Prostatectomy in Patients with Elevated Prostate Specific Antigen Levels

16 May 2024

77

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The results of radiotherapy for isolated elevation of serum PSA levels following radical prostatectomy

16 May 2024

78

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy

16 May 2024

79

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Effect of Adjuvant Radiation Therapy on Prostate Specific Antigen Following Radical Prostatectomy

16 May 2024

80

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

16 May 2024

83

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Effect of external beam radiation therapyon serum prostate-specific antigen

16 May 2024

84

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate Specific Antigen after Irradiation for Prostatic Carcinoma

16 May 2024

85

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate Specific Antigen Levels after Definitive Irradiation for Carcinoma of the Prostate

16 May 2024

87

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation

16 May 2024

88

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

16 May 2024

89

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients

16 May 2024

90

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.

16 May 2024

91

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer.

16 May 2024

92

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

16 May 2024

93

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Use of human prostate-specific antigen in monitoring prostate cancer

16 May 2024

94

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

16 May 2024

95

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma

16 May 2024

96

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer

16 May 2024

97

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer

16 May 2024

98

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

16 May 2024

99

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening

16 May 2024

101

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration

16 May 2024

102

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostatic intraepithelial neoplasia: a premalignant lesion

16 May 2024

105

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Significance of prosttic intraepithelial neoplasia on prostate needle biopsy

16 May 2024

106

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels?

16 May 2024

108

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The effect of digital rectal examination on prostate-specific antigen levels

16 May 2024

109

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Prostate-specific antigen: establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations

16 May 2024

110

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study

16 May 2024

111

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

The effects of exercise and activity on serum prostate specific antigen levels

16 May 2024

112

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen.

16 May 2024

113

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

16 May 2024

114

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands

16 May 2024

118

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

False positive prostate specific antigen values in the sera of women with renal cell carcinoma

16 May 2024

123

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)32422-9

16 May 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7523702%20AND%20SRC:MED&resulttype=core&format=json

20 October 2019

1 reference